Who is sponsoring NCT03028610?

NCT03028610 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03028610?

Interventions in NCT03028610: radiofrequency generator.

What condition does NCT03028610 study?

NCT03028610 studies One or More Uterine Fibroids.

Is NCT03028610 still recruiting?

NCT03028610 is currently completed. Last updated 9 December 2024.

Last reviewed 2024-12-09 · How we verify

NCT03028610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System

Completed NA Last updated 9 December 2024

What this trial tests

NA trial testing radiofrequency generator in One or More Uterine Fibroids in 23 participants. Completed in 13 August 2023.

Timeline

1 January 2016

Primary endpoint
13 July 2023

13 August 2023

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 January 2016
Primary completion	13 July 2023
Estimated completion	13 August 2023
Sites	1 location across Germany

Drugs / interventions tested

radiofrequency generator

Conditions studied

One or More Uterine Fibroids — all drugs for One or More Uterine Fibroids →

Sponsor

University Hospital Tuebingen

Who can join

Adults 18 to 40, female only, with One or More Uterine Fibroids. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, interventional, single-center, longitudinal, single-arm pilot study to evaluate pregnancies following the Acessa™ treatment of uterine myomas in women who desire future childbearing

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03028610 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03028610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing